Steatohepatitis/Metabolic Liver Disease

Top Story

Fibrosis linked with mortality, liver-related morbidity risk in patients with NAFLD

February 6, 2020
FDA News

Antisense oligonucleotide therapy for triglyceride reduction shows positive top-line results

January 29, 2020
Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-ANGPTL3-LRx for the treatment of patients with hypertriglyceridemia, type 2 diabetes…
In the Journals

Individuals with alcohol use disorder have an increased fibrosis risk

January 27, 2020
The risk of fibrosis is highest in young adults with harmful drinking patterns and steatosis, according to data from a population-based study. “Approximately one…

Interim analysis of metabolic modulators shows efficacy in NAFLD

January 14, 2020
Axcella released an update from the ongoing clinical study of two potential therapies for nonalcoholic fatty liver disease that showed the compounds were safe…
More Headlines »